Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Andrew Blauvelt,Nianwen Shi,Najwa Somani,Russel Burge,Baojin Zhu,Terri L Ridenour,Carolyn R Lew,Nicole M Zimmerman,Bilal Atiya,Mwangi J Murage

Journal of the American Academy of Dermatology（2022）

引用 18|浏览8

暂无评分

摘要

Over 24 months, ixekizumab users exhibited better persistence and adherence, and a lower risk of discontinuation than secukinumab users in real-world settings.

查看译文

关键词

dosing,ixekizumab,psoriasis,secukinumab,treatment adherence,treatment discontinuation,treatment persistence,treatment reinitiation,treatment switching

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要